© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
June 14, 2021
Data presented at 2021 ASCO indicated that chimeric antigen receptor therapy with ALLO-501A plus ALLO-647 lymphodepletion showed promise in patients with relapsed/refractory large B-cell lymphoma.
June 08, 2021
Pimitespib significantly improved progression-free survival while prolonging overall survival compared with placebo to treat patients with advanced gastrointestinal stromal tumor.
June 07, 2021
Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.
June 06, 2021
Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.
June 05, 2021
While selumetinib was well-tolerated, it did not drive objective responses.
Patients with pretreated KRAS p.G12C–mutated NSCLC experienced a continued durable clinical benefit with sotorasib.
June 04, 2021
Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.
Data from the KEYNOTE-564 trial presented at ASCO indicate benefit of pembrolizumab therapy in patients with clear cell renal cell carcinoma who were receiving therapy in the adjuvant setting.
April 15, 2021
In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.
April 12, 2021
The selective MCL-1 inhibitor AMG 176 plus gilteritinib as a combination treatment synergistically targeted preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.